astrazeneca glp 1 drug AstraZeneca, Eccogene Enter Exclusive License Agreement for GLP-1 LLY Stock Climbs As Oral

This putative mechanism shares similarities with metformin, the first-line medication for type 2 diabetes, rather than with incretin-based therapies

Considering the short half-life of small molecule oral GLP-1 receptor agonists, perhaps approaches to increase the duration of small molecules with a modified-release formulation may lead to improvements in long-term cardiovascular benefits

[DOI] [PubMed] [Google Scholar] 52.Salcedo I., Tweedie D., Li Y., Greig N.H

Costs were in 2019 US dollars

Cell Metab 3:153165 Nauck MA, Quast DR, Wefers J, Pfeiffer AFH (2021) The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update